Our Business Segments

Endo International plc

Headquartered in Dublin, Ireland

$3.47 billion

in revenue in 2017

U.S. Generic Pharmaceuticals

Headquartered in Chestnut Ridge, New York

Among the largest U.S. generics company based on market share. Develops, licenses, manufactures, markets and distributes safe, innovative and cost-effective pharmaceuticals with a focus on first-to-file or first-to-market opportunities and high-barrier-to-entry products that are difficult to formulate, difficult to manufacture, or that face complex legal and regulatory challenges. The generics R&D pipeline consists of over 175 products including approximately 100 ANDAs pending with the FDA.

$2.28 billion

in revenue in 2017

Segment Milestones

  • Launched 17 new products including 4 sterile injectable products and the generic version of Sabril® Powder for Oral Solution, a first-to-market generic to launch in the specialty pharmacy market
  • Filed 12 regulatory submissions
  • Continued strong growth of Sterile Injectables which grew 23% year-over-year
  • Continued to restructure our generics manufacturing network to drive greater efficiency

Key Product Lines*

  • Sterile Injectable Products
  • New launches / Alternative Dosage Products
  • Base business

*Note: In February 2018, we made changes to the way we manage and evaluate our business. As a result, our Sterile Injectables portfolio, which was part of our U.S. Generic Pharmaceuticals segment as of December 31, 2017, will be presented as a new segment named U.S. Branded – Sterile Injectables starting in the first-quarter 2018.

U.S. Branded Pharmaceuticals

Headquartered in Malvern, Pennsylvania

Focused on developing and marketing high-value, quality branded pharmaceutical products for patients in need. Endo Pharmaceuticals’ specialty portfolio includes products for urology, men’s health, orthopedics and endocrinology, with product development underway in medical aesthetics.

$958 million

in revenue in 2017

Segment Milestones

  • Increased demand for XIAFLEX® in Peyronie’s Disease and Dupuytren’s Contracture with sales growing 12% in 2017
  • Initiated new marketing platforms including customer activation through digital direct-to-consumer outreach to drive further growth of XIAFLEX®
  • Enhanced focus on Specialty Branded Pharmaceuticals yielded growth of 11% year-over-year
  • Phase 3 design and preliminary launch planning for collagenase clostridium histolyticum (CCH) in cellulite initiated; Two Phase 3 studies commenced in February 2018
  • Voluntarily removed OPANA® ER from the market

Key Product Lines

  • XIAFLEX®
  • SUPPRELIN® LA
  • TESTOPEL®
  • NASCOBAL®
  • AVEED®

International Pharmaceuticals

Our International Pharmaceuticals businesses included: Paladin Labs, headquartered in Montreal, Canada; SOMAR, headquartered in Mexico City, Mexico; and Litha, headquartered in Midrand, South Africa.

$230 million

in revenue in 2017

Segment Milestones

  • Paladin Labs grew 2% year-over-year
  • Paladin Labs filed 2 sterile injectables from our existing U.S. portfolio
  • Paladin Labs in-licensed ENVARSUS® for the Canadian market
  • Divested non-core International businesses, Litha and Somar in July and October 2017, respectively
By the Numbers